SCHEMBL417053

SCHEMBL417053

CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.83
LMNA P02545 2/20 0.83
ALDH1A1 P00352 2/20 0.83
PRKD3 O94806 1/20 0.83
PRKCG P05129 1/20 0.83
PRKCB P05771 1/20 0.83
PRKCA P17252 1/20 0.83
PRKCH P24723 1/20 0.83
PRKCI P41743 1/20 0.83
PRKCE Q02156 1/20 0.83
PRKCQ Q04759 1/20 0.83
PRKCZ Q05513 1/20 0.83
PRKCD Q05655 1/20 0.83
PRKD1 Q15139 1/20 0.83
MAPK1 P28482 1/20 0.83
SMN1; SMN2 Q16637 1/20 0.83
MEN1 O00255 1/20 0.83
GMNN O75496 1/20 0.83
BLM P54132 1/20 0.83
KMT2A Q03164 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10565337 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL15477735 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10564175 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2582886 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL1532761 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2733343 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10565746 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10602960 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL4320248 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2734265 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090505-A1 FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2026-04-30 WO claimed
EP-4726038-A1 EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE Rinuagene Biotechnology Co., Ltd. (CN) 2026-04-15 EP claimed
US-20250302860-A1 DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-10-02 US claimed
EP-4578465-A1 INFECTION DETECTION SYSTEM Paul Hartmann Aktiengesellschaft (DE) 2025-07-02 EP claimed
WO-2025092866-A1 MULTIVALENT INFLUENZA MRNA VACCINE 仁景(苏州)生物科技有限公司 2025-05-08 WO claimed
US-20240366747-A1 UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-11-07 US claimed
US-12053552-B2 Functional wound dressing PAUL HARTMANN AG (DE) 2024-08-06 US claimed
EP-4370152-A1 UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-05-22 EP claimed
EP-3569261-B1 FUNCTIONAL WOUND DRESSING HARTMANN PAUL AG (DE) 2024-04-03 EP claimed
WO-2023288263-A1 UNIVERSAL VACCINE FOR INFLUENZA VIRUS BASED ON TETRAMERIC M2 PROTEIN INCORPORATED INTO NANODISCS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2023-01-19 WO claimed
CN-115515598-A Pharmaceutical composition of niclosamide 德克萨斯大学系统董事会 2022-12-23 CN claimed
US-20210361822-A1 FUNCTIONAL WOUND DRESSING PAUL HARTMANN AG (DE) 2021-11-25 US claimed
US-10660854-B2 Thermostable vaccines based on ether lipids and native viral envelope proteins BATAVIA BIOSCIENCES INC. (US) 2020-05-26 US claimed
EP-3569261-A1 FUNCTIONAL WOUND DRESSING Paul Hartmann AG (DE) 2019-11-20 EP claimed
US-20180085313-A1 Thermostable Vaccines Based On Ether Lipids And Native Viral Envelope Proteins BATAVIA BIOSCIENCES INC. 2018-03-29 US claimed
US-20120021130-A1 METHOD FOR INHIBITING DECOMPOSITION OF METAL SULFIDE-CONTAINING MATERIAL THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK, STONY BROOK (US) 2012-01-26 US claimed
US-7153541-B2 Method for inhibiting oxidation of metal sulfide-containing material U.S. DEPARTMENT OF ENERGY 2006-12-26 US claimed
US-20050036930-A1 Method for inhibiting oxidation of metal sulfide-containing material U.S. DEPARTMENT OF ENERGY 2005-02-17 US claimed
EP-1033972-B1 DRUG DELIVERY SYSTEM WITH TWO-STEP TARGETING EDWARDS KATARINA (SE) 2003-08-27 EP claimed
WO-2003047768-A1 METHOD FOR INHIBITING OXIDATION OF METAL SULFIDE-CONTAINING MATERIAL THE RESEARCH FOUNDATION (US) 2003-06-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10660854-B2 Thermostable vaccines based on ether lipids and native viral envelope proteins MGLL, DDOST, PLTP AKT1 3779/4885LMNA 1750/4885ALDH1A1 4772/4885
US-20180085313-A1 Thermostable Vaccines Based On Ether Lipids And Native Viral Envelope Proteins MGLL, DDOST, PLTP AKT1 3779/4885LMNA 1750/4885ALDH1A1 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.